中国经济网北京1月14日讯 兰州银行(001227.SZ)今日收报2.32元，跌幅1.28%，总市值132.14亿元。 目前该股处于破发状态。 兰州银行于2022年1月17日在深交所上市，发行价3.57元/股，保荐机构、主承销商为中信建投证券 股份有限公司，保荐代表人为曾琨杰、田斌。 兰州银行上市募集资金总额为20.33亿元，募集资金净额为19.68亿元。兰州银行招股书显示，本次 发行募集资金扣除发行费用后，将全部用于充实资本金，以提高资本充足水平，增强综合竞争力，提升 股东价值。 兰州银行首次上市发行费用为6503.04万元，其中保荐机构中信建投证券股份有限公司获得保荐及 承销费用5272.09万元。 (责任编辑：田云绯) ...

中国经济网北京1月14日讯 亨迪药业(301211.SZ)今日收报13.20元，跌幅2.87%，总市值55.12亿元。 目前该股处于破发状态。 亨迪药业首次公开发行股票募集资金总额为15.48亿元，募集资金净额为14.01亿元，较原拟募集资 金多2.10亿元。亨迪药业此前披露的招股书显示，该公司原拟募集资金11.90亿元，拟分别用于年产 5,000吨布洛芬原料药项目、年产1,200吨原料药项目、年产12吨抗肿瘤原料药项目、补充流动资金项 目。 亨迪药业于2021年12月22日在深交所创业板上市，公开发行新股6000万股，发行价格为25.80元/ 股，保荐机构为国泰君安证券股份有限公司（现更名为国泰海通证券股份有限公司），保荐代表人为李 懿、王栋。 (责任编辑：田云绯) 2025年8月1日，亨迪药业发布公告，拟每10股转增4.5股。 亨迪药业首次公开发行股票的发行费用为1.47亿元，其中，承销费用1.32亿元。 2023年5月24日，亨迪药业发布公告，拟每10股转增2股，派息（税前）4元。 ...

2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股 东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产 生的现金流量净额为-2.61亿元。 (责任编辑：田云绯) 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为 329,140.14万元。智翔金泰实际募资净额比原拟募集资金金额少68,859.86万元。智翔金泰于2023年6月15 日披露的招股说明书显示，该公司拟募集资金398,000.00万元，用于抗体产业化基地项目一期改扩建、 抗体产业化基地项目二期、抗体药物研发项目、补充流动资金。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元（不含税），其中，保荐承销费16,495.98 万元。 智翔金泰已连亏4年3季。2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿 元、-5.76亿元、-8.01亿元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿 元、-8.13亿元、-8.04亿元。 中国经济网北 ...

(责任编辑：田云绯) 思科瑞首次公开发行股票的发行费用总额为13,574.34万元（发行费用均为不含税金额），其中，中 国银河证券股份有限公司获得承销及保荐费用10,760.38万元。 思科瑞2025年9月20日发布关于实施其他风险警示暨停牌的公告。因思科瑞于2025年9月19日收到中 国证监会四川监管局下发的《行政处罚事先告知书》（川证监处罚字【2025】6号）。依据《事先告知 书》载明的内容，根据《上海证券交易所科创板股票上市规则（2025年4月修订)》相关规定，公司股票 将被实施其他风险警示。A股股票简称由"思科瑞"变更为"ST思科瑞"；扩位简称由"思科瑞微电子"变更 为"ST思科瑞微电子"；实施风险警示的起始日：2025年9月23日。 中国经济网北京1月14日讯 ST思科瑞(688053.SH)今日收报48.68元，跌幅4.70%，总市值48.68亿 元。目前该股处于破发状态。 思科瑞于2022年7月8日在上交所科创板上市，公开发行的股票数量为2500.00万股，发行价格为 55.53元/股，保荐人（主承销商）为中国银河证券股份有限公司，保荐代表人为陈召军、姚召五。 思科瑞首次公开发行股票募集资金总额 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed penalties on Yuancheng Environment Co., Ltd. and its actual controller, Zhu Changren, for financial misconduct, including false reporting in annual reports and misleading information in stock issuance documents [1][4]. Group 1: Financial Misconduct - Yuancheng Environment's annual reports from 2020 to 2022 contained false records, with inflated costs and revenues related to the Yuelongshan project, resulting in a total inflated operating cost of approximately 158.44 million yuan, inflated operating income of about 208.90 million yuan, and inflated total profit of around 50.46 million yuan [2]. - The inflated figures for the 2020 annual report included an operating cost increase of approximately 115.08 million yuan, operating income increase of about 153.56 million yuan, and profit increase of around 38.48 million yuan, representing 22.75%, 21.48%, and 36.60% of the disclosed amounts, respectively [2]. - For 2021, the inflated operating costs were about 25.08 million yuan, with operating income and profit inflated by approximately 36.17 million yuan and 11.09 million yuan, representing 5.99%, 6.31%, and 19.32% of the disclosed amounts, respectively [2]. - In 2022, the inflated operating costs were around 18.28 million yuan, with operating income and profit inflated by approximately 19.17 million yuan and 885,931.40 yuan, representing 7.22%, 5.86%, and 1.62% of the disclosed amounts, respectively [2]. Group 2: Stock Issuance Misrepresentation - In 2022, Yuancheng Environment fabricated significant false content in documents related to its non-public stock issuance, which raised approximately 284.55 million yuan [4]. - The financial data cited in the stock issuance documents regarding the Yuelongshan project for 2020 and 2021 was found to be untrue and inaccurate [4]. Group 3: Regulatory Actions and Penalties - The CSRC has ordered Yuancheng Environment to rectify its practices, issued a warning, and imposed a fine of approximately 37.45 million yuan [5]. - Zhu Changren, as the actual controller, received a warning and a fine of 28 million yuan for his role in the misconduct [5]. - Other executives, including Zhou Jinhai, Yao Lihua, and Chen Ping, also faced penalties for failing to ensure the accuracy and completeness of financial disclosures, with fines ranging from 200,000 to 5 million yuan [6].

Group 1 - The stock of Zhongzi Technology (688737.SH) closed at 23.99 yuan, with a decline of 2.24%, resulting in a total market capitalization of 2.868 billion yuan, currently in a state of breaking issue [1] - Zhongzi Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 22, 2021, with an initial public offering of 21.5087 million shares at a price of 70.90 yuan per share [1] - The highest price recorded on the first day of trading was 70.50 yuan, marking the highest price since its listing [1] Group 2 - The total funds raised from the initial public offering amounted to 1.525 billion yuan, with a net amount of 1.407 billion yuan after deducting issuance costs, which was 52.7168 million yuan less than the original plan [1] - The total issuance costs for the initial public offering were 118 million yuan, including an underwriting and sponsorship fee of 93.5123 million yuan [2] - As of July 11, 2023, the company announced a capital distribution plan, with a total share capital of 86,034,976 shares, and a capital increase of 34,207,910 shares, resulting in a new total share capital of 120,242,886 shares [2]

Core Viewpoint - ST Huilun (300460) has been penalized by the China Securities Regulatory Commission (CSRC) for violations related to information disclosure and financial misreporting, including significant omissions in its 2020 annual report and false records in its 2021 and 2022 reports [1][3][5]. Group 1: Violations and Penalties - ST Huilun and its actual controller Zhao Jiqing received a notice of administrative penalty from the CSRC for failing to disclose related party fund occupation in its 2020 annual report, which constituted a significant omission [1][2]. - The company was found to have occupied funds amounting to 28,330,000 yuan in 2020, which represented 5.12% of its disclosed net assets for that year [1]. - The CSRC imposed a fine of 3 million yuan on ST Huilun and 4 million yuan on Zhao Jiqing, along with penalties for other executives involved in the violations [7]. Group 2: Financial Misreporting - ST Huilun inflated its cost and revenue figures in its 2021 and 2022 annual reports to cover up the fund occupation, resulting in a reported increase in costs of 8,639,070.52 yuan in 2021 and 23,954,692.38 yuan in 2022 [3][4]. - The company falsely recorded revenue of 25,489,938.60 yuan in 2021 and 62,333,644.39 yuan in 2022, which accounted for 3.89% and 15.79% of the reported revenue for those years, respectively [5]. - The inflated profits for 2021 and 2022 were reported as 8,445,707.65 yuan and 21,314,134.88 yuan, respectively, with significant discrepancies in the financial statements [5][6]. Group 3: Management Accountability - Zhao Jiqing, as the chairman, was directly responsible for the violations, including the failure to disclose fund occupation and the inflation of financial figures [6][7]. - Other executives, including Han Qiaoyun and Deng Youqiang, were also held accountable for their roles in the misreporting and were fined accordingly [6][7]. - The management's failure to ensure accurate reporting led to significant penalties and highlighted the need for improved governance and compliance within the company [6][7].

中国经济网北京1月14日讯 国家金融监督管理总局网站昨日公布的驻马店监管分局行政处罚信息公示表 （驻金罚决字〔2025〕77-79号）显示，中国人民财产保险股份有限公司驻马店市分公司存在四项违法 违规行为，一是农险理赔平均赔付；二是虚列车险与农险费用；三是虚挂中介套取费用；四是保险宣传 销售违反监管规定。 | 序 | 宗事人 | 行政处罚 | 主要违法违规 | 行政处 | 作出决 | | --- | --- | --- | --- | --- | --- | | 름 | 名称 | 决定书文 | 行为 | 罚内容 | 定机关 | | | | 름 | | | | | 1 | 中国人 民财产 | 字 | 农险理赔平均 赔付;虚列车 | 处罚款 | | | | | 驻金罚决 | | 警告并 | | | | 保险股 | | 险与农险费 | | | | | 份有限 | | 用:虚挂中介 | | | | | | (2025) | | 52.4万 | | | | 公司驻 | 77号 | 套取费用;保 | 元 | | | | 马店市 | | 险宣传销售违 | | | | | 分公司 | | 反监管规定 | | | | | 赵春 ...

"冬季是暖身养生产品的销售旺季，今年这两款爆款的订单量同比增长120%，日均加工艾草30吨，月均 发货150吨，预计年产值能突破6000万元，订单已经排到了下个月。"公司负责人张飞介绍，随着产品生 产工艺和质量的不断提升，"独树艾草"的品牌知名度随之提高不少，产品不仅畅销国内各地，还通过直 播带货模式进一步拓宽了销售渠道。 乡村振兴，产业先行。作为独树镇回创企业代表，南阳立健生物科技有限公司的发展红利，正转化为带 动群众增收致富的有效动能。公司依托本地千亩艾田建立专属原料基地，以高于市场价10%的标准收购 村民种植的艾草，既保障了原料的新鲜度与品质稳定性，更让田间地头的艾草变身村民增收的"致富 草"；企业常年吸纳300余名周边村民稳定就业，人均月收入超3000元，不少村民实现"家门口挣钱、顾 家两不误"的心愿。当地党委政府借势发力，依托该公司推出的"工厂供货+个人网店"创业帮扶模式，组 织专业团队开展电商运营、直播技巧等培训，从店铺装修、产品上架到客户沟通全程指导，助力100余 户村民开启电商创业之路。 隆冬时节，由河南省南阳市方城县独树镇南阳立健生物科技有限公司生产的艾草暖身宝和艾草泡脚包， 凭借精准品控与 ...

中国经济网北京1月14日讯 华森制药(002907.SZ)昨日晚间发布公告称，公司于近日收到公司控股股东成 都地方建筑机械化工程有限公司（以下简称"成都地建"或"控股股东"）及其一致行动人游洪涛、王瑛、 上海添橙投资管理有限公司－添橙添利一号私募证券投资基金（以下简称"添橙添利一号私募基金"） （以下合称"信息披露义务人"）出具的《简式权益变动报告书》。 本次权益变动前信息披露义务人合计持有华森制药股份292,317,525股，占华森制药总股本的70.00%。 2025年1月23日至2026年1月13日期间，成都地建通过集中竞价及大宗交易的方式减持华森制药股份 14,373,176股，占华森制药总股本3.44%；游洪涛通过大宗交易方式减持华森制药股份5,965,965股，占 华森制药总股本1.43%；添橙添利一号私募基金通过集中竞价方式减持华森制药股份540,780股，占华森 制药总股本0.13%。 2025年1月23日至2026年1月13日期间，华森制药的加权均价为16.894元/股，以此计算，信息披露义务 人合计减持华森制药20,879,921股，减持金额约为35,274.54万元。 本次权益变动前，信息 ...